Myeloablative conditioning regimens increase the efficiency of adoptive T-lymphocyte transfer in metastatic melanoma

References

[1] Romero Р., Cerottini J.C., Speiser D.E. The human T-cell response to melanoma antigens. Adv. Immunol. 2006; 92: 187—224.

[2] Stockert E., Jflger E., Chen Y. et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 1998; 187(8): 1349-54.

[3] Huang S.K., Okamoto T., Morton D.L., Hoon D.S. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J. Invest. Dermatol. 1998; 111(4): 662—7.

[4] Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004; 10(9): 909—15.

[5] Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 2006; 6(5): 383-93.

[6] Rosenberg S.A., Yannelli J.R., Yang J.C. et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994; 86(15): 1159-66.

[7] Cheever M.A., Greenberg P.D., Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J. Immunol. 1980; 125(2): 711—4.

[8] North R.J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T-cells. J. Exp. Med. 1982; 155(4): 1063-74.

[9] Dudley M.E., Wunderlich J.R., Robbins P.F. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298(5594): 850—4.

[10] Shen X., Zhou J.5 Hathcock K.S. et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 2007; 30(1): 123—9.

RIGHTS & PERMISSIONS

Eco-Vector